Form 8-K - Current report:
SEC Accession No. 0001104659-24-116420
Filing Date
2024-11-12
Accepted
2024-11-12 08:10:18
Documents
21
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2426982d2_8k.htm   iXBRL 8-K 26615
2 EXHIBIT 99.1 tm2426982d2_ex99-1.htm EX-99.1 112842
3 GRAPHIC image_001.jpg GRAPHIC 4057
4 GRAPHIC image_002.jpg GRAPHIC 4057
5 GRAPHIC image_002.gif GRAPHIC 2617
6 GRAPHIC image_003.jpg GRAPHIC 4057
7 GRAPHIC image_004.jpg GRAPHIC 4057
8 GRAPHIC image_005.jpg GRAPHIC 4057
9 GRAPHIC image_006.jpg GRAPHIC 4057
  Complete submission text file 0001104659-24-116420.txt   364990

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA syn-20241112.xsd EX-101.SCH 3042
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20241112_lab.xml EX-101.LAB 34240
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20241112_pre.xml EX-101.PRE 22378
23 EXTRACTED XBRL INSTANCE DOCUMENT tm2426982d2_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 241443604
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)